Sectors
Aratana Therapeutics, a US developer of medicines for pets, sets IPO terms.
Epizyme sold 5.1 million shares at $15 each compared to plans to offer 4.285 million shares at between $13 and $15 each.
Celgene owns 14.5% of Epizyme ahead of the initial public offering (IPO), after investing the portfolio company's series C round.
Lanxess-backed converter of feedstocks into chemicals revises IPO terms.
Biogen Idec-backed Portola Pharmaceuticals set to raise around $103.2m on Nasdaq with $469m market cap
Receptos raised $73m in its initial public offering (IPO) on the Nasdaq stock exchange.
The investment banks for the flotation are: Morgan Stanley, Goldman Sachs, JPMorgan Chase and Barclays.
Investment banks Cowan and BMO Capital Markets are advising the initial public offering (IPO), with legal counsel from Lowenstein Sandler and Goodwin Procter.
Ambit plans to list 4.645 million shares at between $13 and $15 each when it floats on the Nasdaq stock exchange.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
